Suning.com's (SHE:002024) executives plan to increase their holdings in the company by no less than 6 million yuan, according to a Wednesday disclosure on the Shenzhen bourse.
The executives, including Chairman Ren Jun, will raise their stake through centralized bidding from Wednesday, May 27 until Aug. 26.
The Chinese retailer's shares jumped 5% at the close.
The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW (Cayman) Therapeutics (HKG:2126) CEO Leo Tian."For us, everything is business as usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly dependent on international cooperation," Reuters quoted Tian as saying.JW is "actively seeking cooperation" with companies outside China for assets in its pipeline, the report said, citing Tian.Global pharmaceutical companies have been ramping up their search for China‑developed experimental drugs in a bid to cut costs before their patents expire, Reuters said.Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Tokyo Kiraboshi Financial Group (TYO:7173) will receive a dividend of 8 billion yen from its consolidated subsidiary, Kiraboshi Bank, on June 1, to help fund a capital increase of UI Bank.The dividend will be recorded as operating income in the company's non-consolidated financial statements for the fiscal year ending March 31, 2027, according to a Tokyo bourse filing on Wednesday.However, because the dividend originates from a consolidated subsidiary, it will have no impact on the Group's consolidated financial results for the same period.The disclosure was made as the event requires submission of an extraordinary report under Japan's Financial Instruments and Exchange Act.
SGSG Science & Technology's (SHE:300561) delisting risk was lifted on Wednesday, according to a same-dated filing on the Shenzhen bourse.The software developer received a delisting warning in April 2025 after reporting negative earnings in its 2024 report and failing to execute controls over sales operations.The Shenzhen Stock Exchange approved the company's application to remove the delisting risk after the company underwent rectification in their internal controls.Trading of SGSG's shares were temporarily suspended.